ArticleComputational and structural biotechnology journal2025
gdGSE: An algorithm to evaluate pathway enrichment by discretizing gene expression values.
Article in Computational and structural biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A radiotherapy resistance-related prognostic signature predicts survival and the immune landscape in rectal cancer.Translational cancer research · 2026Article
- SpaGene: A Deep Adversarial Framework for Spatial Gene Imputation.Computational and structural biotechnology journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We proposed gdGSE, a novel computational framework for gene set enrichment analysis. Unlike conventional methods that rely on continuous gene expression values, gdGSE employs discretized gene expression profiles to assess pathway activity. This approach effectively mitigates discrepancies caused by data distributions. This algorithm consists of two steps: (1) applying statistical thresholds binarizing gene expression matrix, and (2) converting the binarized gene expression matrix into a gene set enrichment matrix. Our results demonstrated that gdGSE could robustly extract biological insights from a diverse array of simulated and real bulk or single-cell gene expression datasets. Notably, gene set enrichment scores by gdGSE exhibited enhanced utility in downstream applications: (1) precise quantification of cancer stemness with significant prognostic relevance; (2) enhanced clustering performance in stratifying tumor subtypes with distinct prognoses; and (3) more accurate identification of cell types. Remarkably, the pathway activity scores by gdGSE showed > 90 % concordance with experimentally validated drug mechanisms in patients-derived xenografts and estrogen receptor-positive breast cancer cell lines. Our algorithm proposes that discretizing gene expression values provides an alternative method for evaluating pathway enrichment, applicable to both bulk and single-cell data analysis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.